Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-199 pembrolizumab in metastatic castration-resistant prostate cancer
NL-OMON55373Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in prostate cancer (PCa) (5 cohorts), sponsored by Merck & Co. Primary endpoint: Objective Response Rate. Started Sep 2016; status: active, not recruiting.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON55373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55373.